The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

By updating the genetic code inside mRNA vaccines every year, scientists can keep population-level immunity aligned with ...

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective ...

Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on Thursday, helped by lower production costs and a cutback in research and ...

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans ...

Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $860 million and a loss of $2.15 per ...

CereCura was co-founded by renowned scientist and UBC professor Pieter Cullis, who developed LNPs, the drug delivery system ...

Switching from etravirine- to doravirine-containing regimen maintains viral suppression in people with HIV-1 infection, including those with archived resistance to NNRTIs.